

217577US-0 CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :
SEIJI OHNO ET AL : ATTN: APPLICATION DIVISION
SERIAL NO: NEW APPLICATION :
FILED: HEREWITH :
FOR: NEW DIHYDROPYRIMIDINE
DERIVATIVES

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend this application as follows.

IN THE SPECIFICATION

Page 1, at the top of the page, insert:

TITLE OF THE INVENTION

DIHYDROPYRIMIDINE COMPOUNDS AND COMPOSITIONS

CONTAINING THE SAME

after line 22, insert:

Description of the Background

Page 3, line 24, insert:

SUMMARY OF THE INVENTION

Page 4, after line 14, insert:

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
IN THE CLAIMS

Please cancel Claims 12, 13, 23-25, and 27-30.

Please add the following new Claims:

31. (New) A method of inhibiting activation of N-type calcium channel in a mammal, which comprises administering an effective amount of one or more compounds of Claim 1, to said mammal.

32. (New) A method of inhibiting activation of N-type calcium channel in a mammal, which comprises administering an effective amount of one or more compounds of Claim 14, to said mammal.

33. (New) A method of treating a disease attended by activation of N-type calcium channel in a mammal, which comprises administering one or more of the compounds of Claim 1, to said mammal.

34. (New) The method of Claim 33, wherein said disease is an acute stage of ischemic cerebrovascular disorder caused by cerebral infarction or intracerebral bleeding.

35. (New) The method of Claim 33, wherein said disease is a progressive neurodegenerative disease.

36. (New) The method of Claim 35, wherein said progressive neurodegenerative disease is selected from the group consisting of Alzheimer's disease, AIDS related dementia, Parkinson's disease, dementia due to cerebrovascular disorder and ALS.

37. (New) The method of Claim 33, wherein said disease is neuropathy due to head injury.

38. (New) The method of Claim 33, wherein said disease is spinal injury, diabetes, thromboangitis obliterans, postoperative pain, migraine or visceral pain.

39. (New) The method of Claim 33, wherein said disease is an addiction attended by withdrawal symptoms.

40. (New) A pharmaceutical composition, which comprises:

- a) one or more of the dihydropyrimidine derivatives of Claim 1, and
- b) a pharmaceutically acceptable carrier.

REMARKS

Claims 31-40 have been added. Claims 12, 13, 23-25 and 27-30 have been canceled. Hence, Claims 1-11, 14-22, 26, 31-40 are now active in this case.

New Claims 31-40 are fully supported by the claims and disclosure as filed. No new matter has been added.

Accordingly, it is believed that this application is now in condition for examination on the merits.

Favorable consideration is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

William E. Beaumont
Registration No. 30,996



22850

(703) 413-3000

Fax #: (703) 413-2220

WEB/js I:\atty\WEB\217577US-PR.wpd

Marked-Up Copy
Serial No: New Application
Amendment Filed on: Herewith

IN THE SPECIFICATION

Page 1, at the top of the page, delete

--[SPECIFICATION

NEW DIHYDROPYRIMIDINE DERIVATIVES]

and insert therefor:

TITLE OF THE INVENTION

DIHYDROPYRIMIDINE COMPOUNDS AND COMPOSITIONS

CONTAINING THE SAME

after line 22, insert:

Description of the Background

Page 3, line 24, delete

[Disclosure of the Invention]

and insert therefor:

SUMMARY OF THE INVENTION

Page 4, after line 14, insert:

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

IN THE CLAIMS

Claims 12, 13, 23-25, 27-30 (Canceled).

Claims 31-40 (New).--